Stock Analysis of POINT Biopharma Global Inc (PNT) - Birds Eye View

1W   2W   1M   3M   1Y   2Y   5Y   
Overview
Code PNT
Close 12.50
Change 0.0200 / 0.160 %
Volume 3290.88 K
Vol Change -173636.00 / 5.01 %
IndustryBiotechnology
SectorHealthcare
AIO Strength Index
Technical StrengthNeutral
Growth Index Excellent Growth
Value Index Good Value
Profitability Index Low Profitability Stock
Stability Index Good Stability


Fundamental View of POINT Biopharma Global Inc
PE (TTM)

0.0159

Excellent
Price / Book

0.0136

Excellent
Price / Sales

0.0055

Excellent
Piotroski F Score

6.0

Good
Market Cap

1332.11 M

Enterprise Value

1319.68 M

ROA (TTM)

72.51

Excellent
ROE (TTM)

85.82

Excellent
Net Margin (TTM)

34.43

Excellent
Revenue

%

226579 M
Net Profit

214234 %

98293.21 M
Debt to Equity

0

Excellent
Altman Z Score

1218.52

Excellent
Quick Ratio

23.06

Excellent
Cash Ratio

10.81

Excellent


Highs/Lows of POINT Biopharma Global Inc
PeriodOld priceStock ReturnS&P 500 ReturnsHighLowHigh DateLow Date
One Week12.450.402 % 1.50 % 12.5112.4526-Dec-2322-Dec-23
Two Week14.1611.72 % 0.269 % 14.3512.4313-Dec-2319-Dec-23
One Month13.769.16 % 0.296 % 14.3512.4313-Dec-2319-Dec-23
Three Month6.8283.28 % 5.91 % 14.356.6213-Dec-2302-Oct-23
Six Months9.0837.67 % 19.86 % 14.356.6213-Dec-2302-Oct-23
One year6.8881.69 % 13.35 % 14.356.5813-Dec-2324-Mar-23
Two year5.52126.45 % 53.92 % 14.355.2213-Dec-2309-Mar-22


Technical View of POINT Biopharma Global Inc
RSI

35.38

Neutral
MACD

-0.178

Bearish
ADX

32.85

Bearish
Super Trend

13.41

Strong Bearish
Williams %R

-96.35

Mild Bullish
CCI

-107.81

Bullish


EMA 5

12.61

Mild Bearish
EMA 15

13.09

Mild Bearish
EMA 50

12.74

Strong Bearish
EMA 100

11.65

Bullish
SMA 100

10.93

Bullish
SMA 200

9.79

Bullish
SMA 5 / 20

12.47 / 13.45

Strong Bearish
SMA 15 / 50

13.37 / 13.22

Mild Bullish
SMA 50 / 200

13.22 / 9.79

Strong Bullish




Charts of POINT Biopharma Global Inc


Returns of POINT Biopharma Global Inc with Peers
Period / StockPNTTRVIPHRAMLX
1 Week0.402%-1.43%-1.72%-11.32%
1 Mth-9.16%10.65%-5.15%-1.81%
3 Mth83.28%51.44%-17.85%52.14%
6mth37.67%67.33%-8.20%167.96%
1 Year81.69%255.16%5.10%100.32%
2 Year126.45%664.58%43.86%-30.58%
5 Years-239.81%-44.67%-
charts-
View All Together in Chart      Inline           Tile

Compare Fundamentals of POINT Biopharma Global Inc with Peers
Ratio / StockPNTTRVIPHRAMLX
PE0.0159-25.45-54.37-5.23
P/B0.013611.514.844.95
ROA72.51-41.57-6.21-78.77
ROE85.82-45.24-8.90-94.60
Debt To Equity00.00290.03670.0092
Revenue226579 M
% 		0
% 		419813 K
17.83 % 		87371.00 K
70.30 %
Net Income98293.21 M
214234 % 		-47911.00 K
79.11 % 		-58527.00 K
57.24 % 		-301743.00 K
16534.80 %


Technicals of POINT Biopharma Global Inc with Peers
Technical / StockPNTTRVIPHRAMLX-
ADX32.8537.0111.3828.81
CMF-0.1350.255-0.2590.0186
MFI27.3758.2561.5829.88
RSI35.3859.5137.3037.04
MACD Abv SignalFalseFalseTrueFalse
Price Above 50 MAFalseTrueFalseFalse-
Price Above 200 MATrueTrueFalseTrue-


About : POINT Biopharma Global Inc

Address : 4850 West 78th Street, Indianapolis, IN, United States, 46268
Tel : 647 812 2417
URL : https://www.pointbiopharma.com
Code : PNT, ISIN : US7305411099, Exchange : NASDAQ, Country : USA
Fiscal Year End : December
IPO date : 08_Jul_2020
Employee Count : 129

POINT Biopharma Global Inc., a radiopharmaceutical company, develops and commercializes radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate cancer; and PNT2003, a somatostatin-targeted radioligand, which is in Phase III trial for the treatment of neuroendocrine tumors. The company is also developing PNT2001, a next-generation PSMA-targeting product candidate for the treatment of prostate cancer, which is under preclinical studies; and PNT-2004, a fibroblast activation protein-alpha inhibitor targeting program being developed for use in various tumor types that is under preclinical studies. In addition, it has product candidates being developed on CanSEEK technology sub-licensed from both Bach Biosciences LLC and Avacta Life Sciences Limited. POINT Biopharma Global Inc. was founded in 2019 and is headquartered in Indianapolis, Indiana. As of December 27, 2023, POINT Biopharma Global Inc. operates as a subsidiary of Eli Lilly and Company.


Note : All Data Generated at the End of Trading Hours (EOD Data)